Trastuzumab retreatment after relapse on adjuvant trastuzumab therapy for human epidermal growth factor receptor 2-positive breast cancer: Final results of the retreatment after herceptin adjuvant trial

Clinical Oncology

Volumn 26, Issue 2, 2014, Pages 81-89

  Lang I ^a   Bell, R ^b   Feng, F Y ^c   Lopez, R I ^d   Jassem, J ^e   Semiglazov, V ^f   Al Sakaff, N ^g   Heinzmann, D ^g   Chang, J ^h  

^a NATIONAL INSTITUTE OF ONCOLOGY   (Hungary)

^b GEELONG HOSPITAL   (Australia)

^c CANCER HOSPITAL   (China)

^d National Oncology Institute   (Panama)

^e MEDICAL UNIVERSITY OF GDANSK   (Poland)

^f N N PETROV RESEARCH INSTITUTE OF ONCOLOGY   (Russian Federation)

^g F HOFFMANN LA ROCHE LTD   (Switzerland)

^h LAKERIDGE HEALTH CORPORATION   (Canada)

Author keywords

HER2 positive; Metastatic breast cancer; Retreatment; Taxane; Trastuzumab

Indexed keywords

DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; PACLITAXEL; TRASTUZUMAB;

ADJUVANT THERAPY; ADULT; AGED; ALOPECIA; ARTICLE; BREAST CANCER; BREAST METASTASIS; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER GROWTH; CANCER PATIENT; CANCER RECURRENCE; CANCER SURVIVAL; CLINICAL ARTICLE; COHORT ANALYSIS; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; DRUG SAFETY; DRUG TREATMENT FAILURE; FEMALE; FOLLOW UP; HUMAN; HUMAN EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; MIDDLE AGED; MONOTHERAPY; OPEN STUDY; OUTCOME ASSESSMENT; OVERALL SURVIVAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RECURRENCE FREE SURVIVAL; RETREATMENT; TREATMENT DURATION; UNSPECIFIED SIDE EFFECT;

HER2-POSITIVE; METASTATIC BREAST CANCER; RETREATMENT; TAXANE; TRASTUZUMAB;

ADULT; AGED; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; COHORT STUDIES; FEMALE; HUMANS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; PACLITAXEL; RECEPTOR, ERBB-2; TAXOIDS;

EID: 84892487804     PISSN: 09366555     EISSN: 14332981     Source Type: Journal    
DOI: 10.1016/j.clon.2013.08.011     Document Type: Article

References (31)

1. American Cancer Society Global cancer facts and figures 2008, American Cancer Society, Atlanta, GA. 2nd ed.
2. Slamon D.J., Godolphin W., Jones L.A., et al. Studies of the HER-2/neu proto-oncogene in human breast and ovarian cancer. Science 1989, 244:707-712.
3. Slamon D.J., Leyland-Jones B., Shak S., et al. Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. NEngl J Med 2001, 344:783-792.
4. Slamon D., Eiermann W., Robert N., et al. Adjuvant trastuzumab in HER2-positive breast cancer. NEngl J Med 2011, 365:1273-1283.
5. Marty M., Cognetti F., Maraninchi D., et al. Randomized phase II trial of the efficacy and safety of trastuzumab combined with docetaxel in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer administered as first-line treatment: the M77001 study group. JClin Oncol 2005, 23:4265-4274.
6. Gianni L., Dafni U., Gelber R.D., et al. Treatment with trastuzumab for 1 year after adjuvant chemotherapy in patients with HER2-positive early breast cancer: a 4-year follow-up of a randomised controlled trial. Lancet Oncol 2011, 12:236-244.
7. Tolaney S.M., Krop I.E. Mechanisms of trastuzumab resistance in breast cancer. Anticancer Agents Med Chem 2009, 9:348-355.
8. Piccart M. Treatment of advanced breast cancer: current status. Anticancer Drugs 1996, 7(Suppl. 2):5-7.
9. Bartsch R., Wenzel C., Hussian D., et al. Analysis of trastuzumab and chemotherapy in advanced breast cancer after the failure of at least one earlier combination: an observational study. BMC Cancer 2006, 6:63.
10. ®) retreatment in patients who relapse following adjuvant trastuzumab therapy: preliminary efficacy data from the RHEA trial. ASCO Breast 2007, Abstract 245.
11. Eisenhauer E.A., Therasse P., Bogarts J., et al. New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 2009, 45:228-247.
12. American Joint Committee on Cancer (AJCC) Cancer staging manual 1997, American Joint Committee on Cancer, Chicago, IL. 5th ed.
13. Clopper C.J., Pearson E.S. The use of confidence or fiducial limits illustrated in the case of the binomial. Biometrika 1934, 26:404-413.
14. Harrell F.E. Regression modeling strategies 2001, Springer, Berlin.
15. Nahta R., Esteva F.J. Trastuzumab: triumphs and tribulations. Oncogene 2007, 26:3637-3643.
16. Inoue K., Nakagami K., Mizutani M., et al. Randomized phase III trial of trastuzumab monotherapy followed by trastuzumab plus docetaxel versus trastuzumab plus docetaxel as first-line therapy in patients with HER2-positive metastatic breast cancer: the JO17360 Trial Group. Breast Cancer Res Treat 2010, 119:127-136.
17. Trastuzumab, summary of product characteristics [cited March 2012]. Available at: http://www.ema.europa.eu/docs/en_GB/document_library/EPAR_-_Product_Information/human/000278/WC500074922.pdf.
18. Wardley A.M., Pivot X., Morales-Vasquez F., et al. Randomized phase II trial of first-line trastuzumab plus docetaxel and capecitabine compared with trastuzumab plus docetaxel in HER2-positive metastatic breast cancer. JClin Oncol 2010, 28:976-983.
19. Cobleigh M.A., Vogel C.L., Tripathy D., et al. Multinational study of the efficacy and safety of humanized anti-HER2 monoclonal antibody in women who have HER2-overexpressing metastatic breast cancer that has progressed after chemotherapy for metastatic disease. JClin Oncol 1999, 17:2639-2648.
20. Original efficacy data [cited March 2012]. Available at: http://www.rochetrials.com/studyResultGet.action?studyResultNumber=WO16229.
21. Original efficacy data [cited March 2012]. Available at: http://www.rochetrials.com/studyResultGet.action?studyResultNumber=MO16982.
22. Baselga J., Cortés J., Kim S.B., et al. Pertuzumab plus trastuzumab plus docetaxel for metastatic breast cancer. NEngl J Med 2012, 366:109-119.
23. Portera C.C., Walshe J.M., Rosing D.R., et al. Cardiac toxicity and efficacy of trastuzumab combined with pertuzumab in patients with trastuzumab-insensitive human epidermal growth factor receptor 2-positive metastatic breast cancer. Clin Cancer Res 2008, 14:2710-2716.
24. Blackwell K.L., Burstein H.J., Storniolo A.M., et al. Randomized study of lapatinib alone or in combination with trastuzumab in women with ErbB2-positive, trastuzumab-refractory metastatic breast cancer. JClin Oncol 2010, 28:1124-1130.
25. Baselga J., Gelmon K.A., Verma S., et al. Phase II trial of pertuzumab and trastuzumab in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer that progressed during prior trastuzumab therapy. JClin Oncol 2010, 28:1138-1144.
26. Verma S., Miles D., Gianni L., et al. Trastuzumab emtansine for HER2-positive advanced breast cancer. NEngl J Med 2012, 367:1783-1791.
27. Morrow P.K., Wulf G.M., Ensor J., et al. Phase I/II study of trastuzumab in combination with everolimus (RAD001) in patients with HER2-overexpressing metastatic breast cancer who progressed on trastuzumab-based therapy. JClin Oncol 2011, 29:3126-3132.
28. Andre F., Campone M., O'Regan R., et al. Phase I study of everolimus plus weekly paclitaxel and trastuzumab in patients with metastatic breast cancer pretreated with trastuzumab. JClin Oncol 2010, 28:5110-5115.
29. Jerusalem G., Fasolo A., Dieras V., et al. Phase I trial of oral mTOR inhibitor everolimus in combination with trastuzumab and vinorelbine in pre-treated patients with HER2-overexpressing metastatic breast cancer. Breast Cancer Res Treat 2011, 125:447-455.
30. Krell J., James C.R., Shah D., et al. Human epidermal growth factor receptor 2-positive breast cancer relapsing post-adjuvant trastuzumab: pattern of recurrence, treatment and outcome. Clin Breast Cancer 2011, 11:153-160.
31. Tjulandin S., Makhson A., Gligorov J., et al. First results of a phase II study of bevacizumab in combination with trastuzumab and capecitabine as first-line treatment of HER2+ LA/MBC. JClin Oncol 2011, 29(Suppl.). abstract 571.